Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2023			2022			2023			2022
Royalties    - RELVAR/BREO	$	45,585		$	55,663		$	150,922		$	170,753
Royalties    - ANORO		11,429			9,943			32,127			28,015
Royalties    - TRELEGY		—			—			—			72,029
Total royalties		57,014			65,606			183,049			270,797
Less: amortization of capitalized fees    paid		(3,456	)		(3,456	)		(10,368	)		(10,368	)
Total net royalty revenue	$	53,558		$	62,150		$	172,681		$	260,429